Literature DB >> 27955829

Open letter on access to the BIA 10-2474 clinical trial data.

Kim Brøsen1, Christian Funck-Brentano2, Heyo K Kroemer3, Munir Pirmohamed4, Matthias Schwab5.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27955829     DOI： 10.1016/S0140-6736(16)32515-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.

Authors:  Joop van Gerven; Milton Bonelli
Journal:  Br J Clin Pharmacol       Date:  2018-05-30       Impact factor: 4.335

Review 2.  Druggable Targets in Endocannabinoid Signaling.

Authors:  Ann M Gregus; Matthew W Buczynski
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 3.  Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals.

Authors:  Joannes A A Reijers; Karen E Malone; Jeffrey J Bajramovic; Richard Verbeek; Jacobus Burggraaf; Matthijs Moerland
Journal:  Br J Clin Pharmacol       Date:  2019-05-29       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.